Skip to content Skip to sidebar Skip to footer

Newsletter

Nick Sundich

1,217 articles published

AI Stocks Blue Chip Stocks Tech Stocks Technology

Here Are 6 Stocks Leading the AI Race! And 6 Stocks that are Losing it!

Stocks Leading the AI Race are going far better than Stocks Losing the AI Race! No company will come our and tell their investors that it is losing the battle - but some investors are harder to persuade than others. Or perhaps companies are actually falling behind in the race. Whatever Google says, the fact…

ByNick SundichSeptember 16, 20250Comments

News Penny Stocks Small Caps Stocks

5 ASX stocks at risk of delisting in the next 6 months

A couple of weeks ago, a list of ASX stocks at risk of delisting was released on the market announcements platforms. The ASX has the right to remove stocks for breaking listing rules (such as failing to lodge the report) or if it is appropriate for some other reason. But it was rare to see…

ByNick SundichSeptember 15, 20250Comments

Consumer Tech Stocks

Can Jumbo Interactive (ASX:JIN) deliver growth living up to its name?

Jumbo Interactive (ASX:JIN) is a lotteries retailer and a provider of a SaaS platform that helps government and charity lottery operators do business. There are several things to like about this company including that it is founder-led, profitable, has a track record of growth and a significant untapped market segment. And a recent…

ByNick SundichSeptember 15, 20250Comments

Large Caps

Should I buy AGL Energy (ASX:AGL) as a turnaround play in FY26?

Should I buy AGL Energy (ASX:AGL)? As consumer seeing their electricity and gas bills go higher and higher, they may think it is a no brainer. After all, sonsumers may cut back on energy usage, but they cannot avoid spending altogether. They may shop around for better deals, but in all seriousness good luck to…

ByNick SundichSeptember 12, 20250Comments

Biotech Stocks Healthcare Stocks Small Caps Stocks

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

It's taken a while to get here, but the US medical device company Imagion Biosystems (ASX: IBX), which listed on the ASX way back in June 2017, is now getting to a really interesting stage of its clinical development, and has just raised $3.5m at 1.5 cents per share to fund this stage. Imagion Biosystems was…

ByNick SundichSeptember 11, 20250Comments

Blue Chip Stocks Education

Here are some ASX directors who sold shares recently and some of the intriguing reasons why

Here are some ASX directors who sold shares recently Jack Gance - Sigma Healthcare (ASX:SIG) a.k.a. Chemist Warehouse Jack Gance co-founded Chemist Warehouse which wanted to list on the ASX for several years, but ultimately took the plunge by a merger with Sigma Healthcare. It is not uncommon for founders to put their shares into…

ByNick SundichSeptember 11, 20250Comments

Bank Stocks Consumer Energy Stocks Renewable Energy Stocks Small Caps Stocks Undervalued Stocks

Plenti (ASX:PLT): Offering investors exposure to the energy transition, but without the high capex

Plenti (ASX:PLT) is not just another small cap lender - it could be the best way to gain exposure to the energy transition. Because it is a lender focused on lending to renewable energy, as well as to consumers for automotives and personal loans. But it is the first of these that has won it…

ByNick SundichSeptember 11, 20250Comments

Consumer Small Caps Stocks

OFX (ASX:OFX): After backflipping on its growth promises and spending months in the doldrums, maybe there’s light at the end of the tunnel?

OFX (ASX:OFX) shares shed more than two thirds of their value from October 2024 to June 2025 after a weak trading update. But its most recent trading update has shown there might be hope for shareholders. OFX Share price chart, log scale (Source: Google) Introduction to OFX OFX was founded in 1998 by Matthew Gilmour and Gary…

ByNick SundichSeptember 10, 20250Comments

Biotech Stocks Healthcare Stocks

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

4 years after listing and over 7 years after its founding, Artrya (ASX:AYA) achieved the aspiration of most ASX medtechs, in obtaining FDA approval. Its Salix suite of products aims to improve the detection and treatment of Coronary Artery Disease (CAD), which is a major cause of heart attacks. Entering the US was always this company's…

ByNick SundichSeptember 10, 20250Comments

4 ASX stocks that Australian Ethical bought or sold recently

Blue Chip Stocks Education

6 ASX stocks that Australian Ethical bought or sold recently

We often like to look at shares that well known ASX fund managers are trading, and today we're looking at a few stocks that Australian Ethical bought or sold recently. Australian Ethical (ASX:AEF) is one of the best known money managers in Australia with over $10bn in FUM and one of the most consistent performers so…

ByNick SundichSeptember 10, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Nick Sundich

Here Are 6 Stocks Leading the AI Race! And 6 Stocks that are Losing it!

5 ASX stocks at risk of delisting in the next 6 months

Can Jumbo Interactive (ASX:JIN) deliver growth living up to its name?

Should I buy AGL Energy (ASX:AGL) as a turnaround play in FY26?

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

Here are some ASX directors who sold shares recently and some of the intriguing reasons why

Plenti (ASX:PLT): Offering investors exposure to the energy transition, but without the high capex

OFX (ASX:OFX): After backflipping on its growth promises and spending months in the doldrums, maybe there’s light at the end of the tunnel?

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

6 ASX stocks that Australian Ethical bought or sold recently

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Nick Sundich

Add Your Heading Text Here